Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Brain Injury Advocates Team Up to "Tackle TBI" in New Public Service Announcement

Helius Medical Technologies,Inc.
Posted on: 10 Nov 16

Helius Medical Technologies (TSX:HSM, OTCQB:HSDT) (“Helius” or the “Company”) in partnership with the Brain Injury Association of America, has launched Tackling TBI,” a new Public Service Announcement (PSA) featuring patient and veteran advocate Montel Williams and former NFL player Marvin Washington. The PSA is designed to raise awareness of Traumatic Brain Injury (TBI) and concussions as growing health issues and to provide patients with education, resources and encouragement to participate in clinical trials to support development of new therapies. Information on a Helius sponsored clinical trial for TBI can be found at www.braininjurytrial.com.

This Smart News Release features an interactive multimedia capsule. View the full release here: http://www.businesswire.com/news/home/20161110005168/en/

(Photo: Business Wire)

“Currently more than 5.3 million Americans in the U.S. live with a lifelong disability as a result of a TBI and there are 1.7 million new cases each year,” said Montel Williams. “Our goal is to ensure that the public at large understands the problem and that patients and caregivers understand where to go for resources that can help.”

The PSA featuring Williams and Washington reminds viewers that a TBI can range from subtle to severe, symptoms can take years to progress and that it’s important to speak with a doctor or healthcare professional if they think they’ve had a brain injury. To view the PSA, visit www.tacklingtbi.com.

“We are proud to partner on the launch of this PSA initiative to raise awareness and understanding of brain injury,” said Susan Connors, president and chief executive officer of the Brain Injury Association of America (BIAA). “A diagnosis of TBI can be the start of a misdiagnosed and misunderstood neurological disease. We need to continue to provide help, hope and healing for the millions of Americans who sustain this life-altering, sometimes devastating, injury.”

A TBI is an injury that disrupts the normal function of the brain and can be caused by a host of things such as sports, car accidents, military service, trips, slips or falls. For many people, TBI causes fatigue, headaches, and difficulty with balance or motor skills, slurred speech, or seizures.

About the Brain Injury Association of American (BIAA)

The Brain Injury Association of America is the country’s oldest and largest nationwide brain injury advocacy organization. Our mission is to advance awareness, research, treatment, and education and to improve the quality of life for all people affected by brain injury. BIAA is dedicated to increasing access to quality health care and raising awareness and understanding of brain injury. Further resources and information related to brain injury are available at http://www.BIAUSA.org, BIAA on Facebook and Twitter Page and through the National Brain Injury Information Center (NBIIC) at 1-800-444-6443.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. For more information, please visit www.heliusmedical.com.

To download the “Tackling TBI” PSA and for media resources visit: www.tacklingtbi.com.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including the short form prospectus filed in connection with the Offering, its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005168/en/

Business Wire
www.businesswire.com

Last updated on: 10/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.